DNA(Ginkgo Bioworks Holdings, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $313.84M | $477.71M | $251.46M | $227.04M | $170.16M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$1.83B | −$2.21B | −$864.41M | −$559.76M | −$315.28M |
| 净利润 | −$1.83B | −$2.10B | −$892.87M | −$547.03M | −$312.76M |
| 经营现金流 | −$253.82M | −$252.20M | −$295.50M | −$319.58M | −$171.06M |
| 自由现金流 | −$310.34M | −$304.47M | −$336.30M | −$382.13M | −$178.72M |
| 摊薄每股收益 | $-55.60 | $-50.20 | $-18.37 | $-10.54 | $-5.64 |